Drug Profile
Research programme: kinase-inhibiting RNase attenuators - OptiKira
Alternative Names: Cell death inhibitors - OptiKira; ERN1 protein inhibitors - OptiKira; Small molecule therapeutics - OptiKiraLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator OptiKira
- Developer Charles River Laboratories; OptiKira
- Class Antifibrotics; Antihyperglycaemics; Eye disorder therapies; Hepatoprotectants; Neuroprotectants; Small molecules
- Mechanism of Action Cell death inhibitors; ERN1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Diabetes mellitus; Hepatic fibrosis; Pulmonary fibrosis; Retinitis pigmentosa
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA (Parenteral)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA (Parenteral)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)